Socio-economic burden of atrial fibrillation in the Russian Federation: dynamics over 12 years
https://doi.org/10.37489/2588-0519-2023-2-53-58
Abstract
Relevance. Diseases of the cardiovascular system remain one of the main causes of death worldwide. The incidence of cardiovascular and circulatory diseases increased by one third between 1990 and 2010. The prevalence of atrial fibrillation (AF) ranges from 2.5–3.5% in the general population of patients to 9–17% in individuals aged 80 years and older.
The aim of the study is to analyze the costs of the Russian healthcare system for various types of treatment of atrial fibrillation.
Materials and methods. The assessment of the present economic burden of AF included an assessment of such direct costs as inpatient treatment, outpatient visits, treatment in a day hospital, medical support, treatment of complications of AF.
Results. The socio-economic burden of AF in the Russian Federation for 2022 without surgical treatment amounted to 196.44 billion rubles per year, compared to 2010 and 2018, costs increased by 77% and 73%, respectively.
About the Authors
A. P. Kasimova
Federal State Budgetary Educational Institution of Higher Education “Academician I. P. Pavlov First St. Petersburg State Medical University” of the Ministry of Healthcare of the Russian Federation; R. R. Vreden National Medical Research Centre for Traumatology and Orthopaedics of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Alina R. Kasimova - PhD, Cand. Sci. Med., associate professor of the department of Clinical Pharmacology and Evidence Based Medicine FSBEI HE I. P. Pavlov SPbSMU MOH Russia; Clinical pharmacologist of the Department of Clinical Pharmacologist R. R. Vreden National Medical Research Centre for Traumatology and Orthopaedics MOH Russia
Saint-Petersburg
O. S. Tufanova
R. R. Vreden National Medical Research Centre for Traumatology and Orthopaedics of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Olga S. Tufanova -Clinical pharmacologist of the Department of Clinical Pharmacologist
Saint-Petersburg
A. S. Kolbin
Federal State Budgetary Educational Institution of Higher Education “Academician I. P. Pavlov First St. Petersburg State Medical University” of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Alexey S. Kolbin - Dr. Sci. (Med.), Professor, Head of the Department of Clinical Pharmacology and Evidence-Based Medicine
Saint-Petersburg
References
1. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014 Mar 15;383(9921):999–1008. doi: 10.1016/S0140-6736(13)61752-3
2. Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circ. Res. 2017 Apr 28;120(9):1501–17. doi: 10.1161/CIRCRESAHA.117.309732
3. Morin DP, Bernard ML, Madias C, Rogers PA, Thihalolipavan S, EstesNA 3rd. The State of the Art: Atrial Fibrillation Epidemiology, Prevention, and Treatment. Mayo Clin. Proc. 2016 Dec;91(12):1778–810. doi: 10.1016/j.mayocp.2016.08.022
4. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/ APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017 Oct;14(10):e275–e444. doi: 10.1016/j.hrthm.2017.05.012
5. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019 Jul 9;140(2):e125–e151. doi: 10.1161/CIR.0000000000000665. Epub 2019 Jan 28. Erratum in: Circulation. 2019 Aug 6;140(6):e285. PMID: 30686041.
6. Kolbin A, Tatarsky B, Biserova I, Zagorodnikova K, Balykina Yu, Proskurin M, Belousov D. Socio-economic burden of atrial fibrillation in the Russian Federation. Klini cheskaya farmakologiya i terapiya. 2010;19(4):17–22. (In Russ.).
7. Kolbin AS, Mosikyan AA, Tatarsky BA. Socioeconomic burden of atrial fibrillations in Russia: seven-year trends (2010–2017). Journal of Arrhythmology. 2018;(92):42–8. (In Russ.).
8. General Tariff Agreement of the Ministry of Health of St. Petersburg, 2022 [Internet]. (In Russ.). Доступно по: https://spboms.ru/page/docs.
9. The State Register of marginal selling prices [Internet]. (In Russ.). Доступно по: http://grls.rosminzdrav.ru.
10. Clinical recommendations. Atrial fibrillation and flutter. (In Russ.). https://congress-med.ru/assets/files/2020/2020-rossijskie-rekomendaczii-po-fp.pdf.
11. Federal State Statistics Service [Internet]. (In Russ.). Доступно по: https://rosstat.gov.ru/.
12. Serdechnaya E. Fibrillyaciya predserdij: osobennosti klinicheskogo techeniya i vybor strategii lecheniya. 2008 [dissertation]. (In Russ.). Доступно по: https://www.dissercat.com/content/fibrillyatsiya-predserdii-osobennosti-klinicheskogo-techeniya-i-vybor-strategii-lecheniya.
13. Serdechnaya ЕV, Yuryeva SV, Tatarsky BА, et al. Epidemiology of atrial fibrillation. Ekologiya cheloveka. 2006;(11):48–52. (In Russ.).
14. Mikhin VP, Maslennikova YuV, Loukianov MM. Patients with atrial fibrillation and ischemic heart disease: hospitalization structure and antithrombotic therapy (RECVASA AF-KURSK registry). Archive of internal medicine. 2017;7 (3):217–23. (In Russ.). doi: 10.20514/2226-6704-2017-7-3-217-223
15. Federal Law "On Labor Pensions in the Russian Federation" dated December 17, 2001 No. 173-FZ, item 1 Article 7. (In Russ.).
Review
For citations:
Kasimova A.P., Tufanova O.S., Kolbin A.S. Socio-economic burden of atrial fibrillation in the Russian Federation: dynamics over 12 years. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2023;(2):53-58. (In Russ.) https://doi.org/10.37489/2588-0519-2023-2-53-58
Views:
1077
Email this article 